Pre-Market Stock News (June 19, 2007)
(ALTH) Allos Therapeutics trading down 20% after its Phase III study of Efaproxyn failed to meet primary endpoint of improvement in overall survival.(BAY) Bayer raised guidance on Schering integration.(BMY) Bristol-Myers: ...Read Full Story »

